In: Intensive Care Medicine, 2010, vol. 36, no. 1, p. 49-56
|
In: Clinical Infectious Diseases, 2010, vol. 50, no. 4, p. 618-620
|
In: Clinical Infectious Diseases, 2009, vol. 48, no. Supplement_4, p. S260-S270
|
In: Clinical Infectious Diseases, 2009, vol. 49, no. 7, p. 997-1005
|
In: The Lancet Infectious Diseases, 2017, vol. 17, no. 2, p. 153–163
Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it difficult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the first structured survey on the occurrence of carbapenemase- producing Klebsiella pneumoniae and Escherichia coli in European...
|
In: International Journal of Antimicrobial Agents, 2015, vol. 45, no. 6, p. 641–646
Recent clinical isolates of key Gram-negative and Gram-positive bacteria were collected in 2012 from hospitalised patients in medical centres in four European countries (France, Germany, Italy and Spain) and were tested using standard broth microdilution methodology to assess the impact of 4 mg/L avibactam on the in vitro activities of ceftazidime, ceftaroline and aztreonam. Against...
|